Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1987 Mar;23(3):287-93.
doi: 10.1111/j.1365-2125.1987.tb03047.x.

Glyceryl-1-nitrate pharmacokinetics in healthy volunteers

Comparative Study

Glyceryl-1-nitrate pharmacokinetics in healthy volunteers

H Laufen et al. Br J Clin Pharmacol. 1987 Mar.

Abstract

The plasma kinetics and urinary excretion of glyceryl-1-nitrate (G-1-N), a metabolite of glyceryl trinitrate with antianginal potential, were investigated in 10 healthy male volunteers, after intravenous infusion and oral administration of 20 mg G-1-N. The apparent volume of G-1-N distribution was 601 corresponding to 0.761 kg-1 body weight, on average. It is suggested that total body water is the principal biological correlate of the hydrophilic drug. Mean intravenous clearance was 283 ml min-1 or 3.61 ml min-1 kg-1. The average of elimination half-lives were 2.50 +/- 0.36 (s.d.) h after the intravenous and 2.54 +/- 0.40 (s.d.) h after the oral dose. Inter-subject variances of pharmacokinetic parameters were low compared to variances reported for glyceryl trinitrate. The coefficient of intra-subject variation of the elimination half-lives was 8.8%. 5.5% (i.v.) and 5.4% (p.o.) of the administered dose were excreted into urine up to 48 h after the administration. 1% (i.v.) and 1.5% (p.o.) were in the conjugated form. The oral dose was rapidly and almost completely absorbed. The oral bioavailability on the basis of areas under the curve amounted to 88.6% on the average. For clinical use, owing to its high oral bioavailability, long residence in the body, inactivation by metabolic conversion, and good predictability of kinetic parameters, G-1-N offers advantage over glyceryl trinitrate.

PubMed Disclaimer

References

    1. Mol Pharmacol. 1965 Jul;1(1):77-86 - PubMed
    1. J Pharm Sci. 1981 Sep;70(9):1054-8 - PubMed
    1. Arch Int Pharmacodyn Ther. 1971 Jul;192(1):198-9 - PubMed
    1. J Pharmacol Exp Ther. 1972 Jun;181(3):489-97 - PubMed
    1. Arch Int Pharmacodyn Ther. 1972 Apr;196:Suppl 196:165- - PubMed

Publication types

LinkOut - more resources